The New England Journal of Medicine (NEJM) published results from Novo Nordisk's phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions ...

After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the ...

Results from the Phase III REDEFINE 1 trial show that CagriSema led to a 22.7% mean weight reduction at 68 weeks in adults ...

Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial ...

Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...

Novo Nordisk is making a strategic move into one of the world's fastest-growing obesity markets by launching its blockbuster ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...

Novo Nordisk’s new weight-loss drug helped patients lose even more weight on average than its current Wegovy blockbuster ...

This summary covers recent developments in health, including the sentencing of Terren Peizer for insider trading, Novo Nordisk's drug trial results, new plans from health insurers on authorization ...

Investing.com - Morgan Stanley (NYSE: MS) has reiterated an Equalweight rating and DKK550.00 price target on Novo Nordisk ...

Wall Street's main indexes opened subdued on Monday as investors awaited Iran's possible response to U.S. airstrikes on its ...